Scientists at Karolinska Institutet in collaboration with the Estonian Competence Centre on Health Technologies have developed a new gene expression analysis assay that will enable a wider use of blood samples in biomarker discovery and analysis.
Amyotrophic lateral sclerosis (ALS), a lethal motor neurone disease that progressively paralyses patients, has many different genetic causes, according to studies coordinated by the University Medical Center of Utrecht, which has reported the discovery of two new ALS genes.
German scientists have clarified the way in which cancer cells spread from a primary tumour to distant parts of the body in a process called metastasis. It has been known for some time that cancer cells travel through the bloodstream to reach other locations, but how they escape from blood vessels has not been clear.
The Wellcome Trust, one of the largest sources of private medical investment in Europe, has appointed Jim Smith as its director of science, a role that puts him in charge of scientific investigations and oversight of the Trust’s scientific investment portfolio.
Scientists from the Swiss antibody company Humabs BioMed SA have characterised the human immune response to infection from the Zika virus and shown for the first time that antibodies derived from infected patients may not only be useful for developing diagnostics and therapies, but also answer the question of why Zika infections can become more dangerous if a person is infected with Dengue fever later in life.
An international research consortium that is working on a promising antibody for the treatment of influenza has had its work published in the 14 July edition of the journal Cell. The research suggests that the antibody has the potential for treating influenza caused by numerous type A strains.
UK-based Storm Therapeutics Ltd, which is developing small molecules that target RNA-modifying enzymes in cancer, has raised £12 million in Series A equity financing. Two heavy-weight corporate venture capitalists participated in the financing, suggesting interest in the technology.
Researchers at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, have discovered an antibody that can activate a protein called Bak and trigger cell death. In healthy cells Bak remains inert. But when a cell receives a signal to die, the protein mobilises to kill the malignant cell.
Researchers at KU Leuven in Belgium have discovered that the tumour protein 53 (TP53) knows exactly where to bind to a DNA sequence to prevent cancer. Once bound to this location, the protein can activate the right genes to repair damaged cells.
A group of 25 bioscience academics and genomic entrepreneurs have published a paper in Science, calling for support of a project to ‘write’ a synthetic human genome. This comes more than a decade after the Human Genome Project successfully sequenced, or ‘read,’ the three billion DNA base pairs that make up the human genome.